Clinical Trial Update: Assess the Safety and Effectiveness of Once Daily PMR Compared to Twice Daily Pletaal® in Patients With Intermittent Claudication [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing once-daily PMR to twice-daily Pletaal for intermittent claudication has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intermittent Claudication

Drugs mentioned

• PMR
• Pletaal (cilostazol)

Snippet

Sponsor: Genovate Biotechnology Co., Ltd., | Conditions: Intermittent Claudication | Phase 3 | Status: TERMINATED